Overview

7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
Phase:
Phase 2
Details
Lead Sponsor:
Mylan Inc.
Theravance Biopharma R & D, Inc.
Collaborator:
Theravance Biopharma